KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

27.00 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about KalVista Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update

December 07, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 05, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

3 Micro-Cap Stocks That Could Be Moonshots ↗

November 14, 2023

If you are hungry for high-risk returns, then these micro-cap stocks to buy could be your winning ticket to future yields.

Via InvestorPlace

KalVista Pharmaceuticals Presents Real-World Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

November 14, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Recap: KalVista Pharma Q4 Earnings ↗

July 07, 2023

Via Benzinga

Analyst Expectations for KalVista Pharma's Future ↗

April 21, 2023

Via Benzinga

KalVista Pharmaceuticals Announces Phase 3 KONFIDENT Trial Milestone Achieved

November 13, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

November 07, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 03, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

November 02, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Presents Data on HAE Attacks in Patients Receiving Long-Term Prophylaxis at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conference

October 24, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference

September 19, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update

September 07, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 HAEi Regional Conference EMEA

August 28, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 02, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 02, 2023

Via Benzinga

KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Nicole Sweeny as Chief Commercial Officer

July 25, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Presents New HAE Attack Journey Data at 2023 US HAEA National Summit

July 24, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 US HAEA National Summit

July 14, 2023

From KalVista Pharmaceuticals

Via Business Wire

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

July 07, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 05, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology

June 12, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 05, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present Data at the 2023 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)

June 02, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present at Jefferies Global Healthcare Conference

May 31, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day Virtual Conference

May 23, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop

May 08, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 02, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present Data at the 13th C1-inhibitor Deficiency & Angioedema Workshop

April 27, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.